Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.

10 Feb 2005

New brochure helps explain treatment for gynecologic cancers

The American Society for Therapeutic Radiology and Oncology has published a new patient information brochure Radiation Therapy for Gynecologic Cancers: Facts to Help People Understand Their Treatment Options to help educate patients and their families about the treatments available for gynecologic cancers.

7 Feb 2005

Origins of skin cancer melanoma

Researchers at Children's Hospital Boston and the Dana-Farber Cancer Institute have found an important clue about the origins of the deadly skin cancer melanoma.

7 Feb 2005

Third of cancer patients in Europe make use of complementary and alternative medicine

More than a third of cancer patients in Europe make use of complementary and alternative medicine (CAM), according to one of the largest surveys undertaken of CAM in cancer.

3 Feb 2005

Relationship between weight gain and breast cancer survival

Women who are overweight prior to breast cancer diagnosis, or who are lean but gain weight following diagnosis, are more likely to have their disease return or die of the disease, a new study shows. This effect was found to be particularly pronounced among women who had never smoked. The study is published online in the Journal of Clinical Oncology (JCO).

31 Jan 2005

One of the most exciting developments in clinical research in decades

One of the most exciting developments in clinical research in decades is taking place at the University of Leeds, led by our professor of cancer medicine Peter Selby in collaboration with the Medical Research Council.

27 Jan 2005

VCU Gastroenterology research papers ranked 4th in most cited papers

Virginia Commonwealth University’s School of Medicine has been ranked fourth among federally funded U.S. universities based on the average number of citations per research paper published in indexed journals of gastroenterology and hepatology between 1999 and 2003.

26 Jan 2005

Schering and Novartis agree on joint commercialization of novel cancer drug

Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.

25 Jan 2005

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Currently, the limited efficacy of conventional therapies, especially in the case of several oncology and autoimmune and inflammatory disorders (AIID), is creating the need for safe and effective treatment alternatives.

25 Jan 2005

Launch date announced for Abraxane to treat metastatic breast cancer

American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.

25 Jan 2005

Phenoxodiol increases the effectiveness of Docetaxel by at least 100 times

The investigational anti- cancer drug, phenoxodiol, considerably enhances the ability of the drug, docetaxel (Taxotere(R), Sanofi-Aventis), to kill human ovarian cancer cells in the laboratory. The findings are reported in the current issue of Oncology Research.

24 Jan 2005

Call for Anastrozole (Arimidex) to be the new preferred breast cancer treatment option

An international group of breast cancer experts called for the aromatase inhibitor (AI), anastrozole ('Arimidex'), to be considered as the new 'preferred treatment option' for postmenopausal women with early breast cancer.

24 Jan 2005

Racial disparities in access to surgical evaluation

African Americans with esophageal cancer are half as likely as whites to be seen by a surgeon and to receive life-prolonging surgery, a new study shows.

19 Jan 2005

Research leads to new antiangiogenic drugs

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies.

17 Jan 2005

Researchers attack cervical cancer

As more and more promising results of clinical trials on vaccination against human papillomaviruses are published, the more likely it becomes that an HPV vaccine will be the first licensed immunization against a sexually transmitted disease.

17 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Researchers to test new leukemia drug

Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.

12 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

A little anxiety can be a good thing when it comes to cancer symptoms

A little anxiety can be a good thing when it comes to cancer symptoms according to researchers at Washington University School of Medicine in St. Louis. They report that people with low overall anxiety levels were more apt to ignore symptoms of rectal cancer for long periods of time, thereby delaying treatment.

12 Jan 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Oncology News and Research

Further Reading

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

New brochure helps explain treatment for gynecologic cancers

Origins of skin cancer melanoma

Third of cancer patients in Europe make use of complementary and alternative medicine

Relationship between weight gain and breast cancer survival

One of the most exciting developments in clinical research in decades

VCU Gastroenterology research papers ranked 4th in most cited papers

Schering and Novartis agree on joint commercialization of novel cancer drug

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Launch date announced for Abraxane to treat metastatic breast cancer

Phenoxodiol increases the effectiveness of Docetaxel by at least 100 times

Call for Anastrozole (Arimidex) to be the new preferred breast cancer treatment option

Racial disparities in access to surgical evaluation

Research leads to new antiangiogenic drugs

Researchers attack cervical cancer

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Researchers to test new leukemia drug

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

A little anxiety can be a good thing when it comes to cancer symptoms

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Breath Biopsy®: The Complete Guide eBook

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News